100
Participants
Start Date
April 5, 2020
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
Venapuncture
Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of risankizumab.
Patient questionnaires
The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
NOT_YET_RECRUITING
University Hospital Leuven, Leuven
NOT_YET_RECRUITING
AZ Sint-Jan, Bruges
NOT_YET_RECRUITING
AZ Delta Rembert, Torhout
NOT_YET_RECRUITING
AZ Maria Middelares, Ghent
NOT_YET_RECRUITING
AZ Sint-Lucas, Ghent
RECRUITING
University Hospital Ghent, Ghent
NOT_YET_RECRUITING
Private practice Dermatology, Maldegem
University Hospital, Ghent
OTHER